Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
91.15 EUR | +0.08% | +1.14% | +1.63% |
07-05 | Sector Update: Health Care Stocks Steady Premarket Friday | MT |
07-05 | Sector Update: Health Care | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's high margin levels account for strong profits.
- The company is in a robust financial situation considering its net cash and margin position.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The opinion of analysts covering the stock has improved over the past four months.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- For the past year, analysts have significantly revised downwards their profit estimates.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+1.63% | 123B | - | ||
+56.89% | 809B | C+ | ||
+39.52% | 624B | B | ||
-6.55% | 351B | C+ | ||
+7.92% | 289B | C+ | ||
+13.74% | 240B | B+ | ||
+13.83% | 220B | B- | ||
-0.49% | 219B | A+ | ||
+7.94% | 166B | C+ | ||
-2.57% | 157B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- SAN Stock
- 0O59 Stock
- Ratings Sanofi